ClinicalTrials.gg
RecruitingNCT04295473Updated Nov 16, 2026

Reduced Port Laparoscopic Gastrectomy for Gastric Cancer

An interventional study of Reduced port laparoscopic gastrectomy in Laparoscopic and Gastrectomy, sponsored by Nanchong Central Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Nanchong Central Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2020; still recruiting 6 years 8 months later.
Updated Nov 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Reduced port laparoscopic gastrectomy has been adopted in clinical. The safety and outcome of reduced port laparoscopic gastrectomy has not been systematically evaluated. The investigators sought to compare the short and long-term outcome of patients with gastric cancer who underwent reduced port gastrectomy with patients underwent traditional laparoscopic gastrectomy

Read the detailed description

Reduced port laparoscopic gastrectomy has been adopted in clinical. The safety and outcome of reduced port laparoscopic gastrectomy has not been systematically evaluated. The investigators designed a comparative study, which sought to compare the short and long-term outcome of patients with gastric cancer who underwent reduced port gastrectomy with patients underwent traditional laparoscopic gastrectomy. The short-term outcome include surgical complications, postoperative morbidity, postoperative nutrition. The long-term outcome mainly include long-term survival.

02

Conditions studied

  • Laparoscopic
  • Gastrectomy
03

In context

Lead sponsor

Nanchong Central Hospital is the lead sponsor of 21 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed adenocarcinoma of the stomach, T1-T4 stages.
  2. performance status of 0 or 1.
  3. Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. Patients had distant .
  2. oesophageal invasion of more than 3 cm.
  3. Borrmann type 4 or large (more than 8 cm) type 3 carcinoma.
  4. Previous chemotherapy or radiation therapy for any other .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Reduced port laparoscopic gastrectomy

    The definition of reduced port laparoscopic gastrectomy was 1-3 ports used in laparoscopic gastrectomy for gastric cancer.

    Procedure: Reduced port laparoscopic gastrectomy

  • No intervention
    Standard laparoscopic gastrectomy

    5 ports were used in standard laparoscopic gastrectomy

Interventions

  • ProcedureReduced port laparoscopic gastrectomy

    The ports were reduced in the surgery of intervention arm.

06

What researchers measure

Primary outcomes

  1. 5-year survival rate

    Longterm survival for patients with gastrectomy after reduced port laparoscopic gastrectomy

    Time frame: 5 years

  2. 3-year survival rate

    Survival rate for patients with gastrectomy after reduced port laparoscopic gastrectomy

    Time frame: 3 years

Secondary outcomes

  1. Postoperative morbidity rate

    Postoperative morbidity rate for patients with gastrectomy after reduced port laparoscopic gastrectomy

    Time frame: 6 months

  2. Malnutrition rate

    Malnutrition rate for patients with gastrectomy after reduced port

    Time frame: 6 months

  3. Quality of life in PGSAS-45 scale

    The quality of life were assessed using PGSAS-45 scale for patients with gastrectomy after reduced port laparoscopic gastrectomy.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2020 (actual). Primary completion is estimated for Mar 2029, 107 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Mar 2027 → Mar 2029 and completion Mar 2027 → Mar 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2020
First posted
Mar 4, 2020
StartActual
Mar 2, 2020
Primary completionEst.
Mar 1, 2029was Mar 2027
CompletionEst.
Mar 1, 2029was Mar 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 1, 2027→Mar 1, 2029
Nov 16, 2026
Study completion
Mar 1, 2027→Mar 1, 2029
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion Mar 1, 2027→Mar 1, 2029
    Study completion Mar 1, 2027→Mar 1, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04295473
Lead sponsor
Nanchong Central Hospital
Responsible party
Yunhong Tian (Professor, Nanchong Central Hospital) — Principal investigator
First posted
Mar 4, 2020
Start date
Mar 2, 2020
Primary completion
Mar 1, 2029 (estimated)
Completion
Mar 1, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Yunhong Tian, MD
Contact
drtianyunhong@126.com
+86-13508087719
Yunhong Tian, MD
principal investigator · Nanchong Central Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion